Home›Stock Screener›Curis Lifesciences›Financial Statements

Curis Lifesciences Financial Statements

5 Years of Data
2026 - 2022

Curis Lifesciences financial statements. In FY2024, Curis Lifesciences (CURIS) reported revenue ₹9 Cr, net profit ₹1 Cr and EPS ₹24.00, with a net profit margin of 11.1% and ROE of 2.1%. Full financial statements from FY2022 to FY2026 (5 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see CURIS screener.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 11.11% 2024 data
EBITDA Margin 33.33% 2024 data
Operating Margin 30.00% 2024 data
Return on Assets 1.22% 2024 data
Return on Equity 2.13% 2024 data

Balance Sheet Ratios

Current Ratio 9.86 2024 data
Equity Ratio 57.32% 2024 data
Asset Turnover 0.11 2024 data

CURIS Revenue, Net Profit & EBITDA — Year-on-Year Growth

CURIS YoY. Read CURIS dividend history for the complete payout history and dividend yield track record.

Assets Growth
+90.7%
Year-over-Year
Equity Growth
+176.5%
Year-over-Year
Operating Cash Flow Growth
-700.0%
Year-over-Year
Financing Cash Flow Growth
+950.0%
Year-over-Year

CURIS Income Statement — Revenue, EBITDA & Net Profit

Curis Lifesciences revenue ₹9 Cr, EBITDA ₹3 Cr, net profit ₹1 Cr, EPS ₹24.00 (2024) — net profit margin 11.1%. Analyse CURIS FII DII holdings to track promoter, FII and institutional holdings.

Periods ₹ Crores
Particulars Jun 2024
Revenue 9
Expenses 6
EBITDA 3
Operating Profit Margin % 30.00%
Depreciation 0
Interest 0
Profit Before Tax 2
Tax 1
Net Profit 1
Earnings Per Share (₹) 24.00

CURIS Balance Sheet — Assets, Liabilities & Shareholders' Equity

CURIS total assets ₹82 Cr, total equity ₹47 Cr, total liabilities ₹ Cr (2026) — ROE 2.1%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022
ASSETS
Total Assets 82 43 34 30 27
Current Assets 69 31 22 17 15
Fixed Assets 11 11 12 12 12
Capital Work in Progress 1 0 0 0 0
Investments 0 0 0 0 0
Other Assets 69 32 22 18 15
LIABILITIES
Total Liabilities
Current Liabilities 7 9 10 10 13
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 47 17 6 0 -1
Share Capital 8 6 1 1 1
Reserves & Surplus 39 11 5 0 -1

CURIS Cash Flow Statement — Operating, Investing & Financing

Curis Lifesciences operating cash flow ₹-16 Cr, investing ₹-2 Cr, financing ₹21 Cr, net cash flow ₹3 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022
Operating Activities -16 -2 0 3 5
Investing Activities -2 0 0 -1 0
Financing Activities 21 2 0 -3 -5
Net Cash Flow 3 0 0 0 0